Claims for Patent: 9,255,132

Summary for Patent: 9,255,132

Title:	Angiopoietin derived peptides
Abstract:	Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.
Inventor(s):	Kliger; Yossef (Rishon LeZion, IL), Borukhov; Itamar (Ramat-HaSharon, IL), Levy; Ofer (Moshav Mesilat Zion, IL), Tiran; Zohar (Oranit, IL), Wool; Assaf (Kiryat-Ono, IL), Schreiber; Ehud (Ramat-Gan, IL), Amir; Anat (Kibbuttz Kfar Aza, IL), Levine; Zurit (Herzlia, IL), Toporik; Amir (Gan-Shomron, IL)
Assignee:	Compugen Ltd. (Tel-Aviv, IL)
Application Number:	13/920,103
Patent Claims:	1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of: an amino acid sequence as set forth in any one of SEQ ID NOs: 7-9, or a homolog or a derivative thereof, wherein said peptide has antiangiogenic activity, and wherein said peptide having an amino acid sequence as set forth in SEQ ID NO: 7, or the homolog or derivative thereof has at most 56 amino acids, wherein said peptide having an amino acid sequence as set forth in SEQ ID NO: 8, or the homolog or derivative thereof has at most 43 amino acids and wherein said peptide having an amino acid sequence as set forth in SEQ ID NO: 9, or the homolog or derivative thereof has at most 38 amino acids and wherein said homolog or derivative differs from said amino acid sequence by conservative amino acid substitutions. 2. The isolated peptide according to claim 1, wherein said homolog of SEQ ID NO: 7 is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NOs. 98-102, wherein said homolog of SEQ ID NO: 8 is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NOs. 106-110 and wherein said homolog of SEQ ID NO: 9 is selected from the group consisting of the amino acid sequence as set forth in SEQ ID NOs. 116-119. 3. A fusion protein consisting of the peptide of claim 1. 4. A pharmaceutical composition comprising the peptide according to claim 1 and a pharmaceutically acceptable carrier. 5. A pharmaceutical composition comprising the fusion protein according to claim 3 and a pharmaceutically acceptable carrier. 6. The pharmaceutical composition according to claim 4, wherein the pharmaceutically acceptable carrier is a controlled release vehicle, selected from the group consisting of biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles, nanoparticles, microspheres, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres and transdermal delivery systems, implantable or not. 7. The pharmaceutical composition according to claim 5, wherein the pharmaceutically acceptable carrier is a controlled release vehicle, selected from the group consisting of biocompatible polymers, other polymeric matrices, capsules, microcapsules, nanocapsules, microparticles, nanoparticles, microspheres, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres and transdermal delivery systems, implantable or not. 8. A method of treating a disease or a condition selected from the group consisting of ocular disease, cancer, chronic inflammatory or autoimmune disease, vascular anomaly, cardiovascular disease, fibrotic or connective tissue related condition, comprising administering a pharmaceutically effective amount of the peptide according to claim 1, to a subject in need thereof, wherein said peptide is administered alone or in combination with another therapeutic agent. 9. A method of treating a disease or a condition selected from the group consisting of ocular disease, cancer, chronic inflammatory or autoimmune disease, vascular anomaly, cardiovascular disease, fibrotic or connective tissue related condition, comprising administering a pharmaceutically effective amount of the fusion protein according to claim 3, to a subject in need thereof, wherein said fusion protein is administered alone or in combination with another therapeutic agent. 10. A method of treating a disease or a condition selected from the group consisting of ocular disease, cancer, chronic inflammatory or autoimmune disease, vascular anomaly, cardiovascular disease, fibrotic or connective tissue related condition, comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to claim 4, to a subject in need thereof, wherein said pharmaceutical composition is administered alone or in combination with another therapeutic agent. 11. A method of treating a disease or a condition selected from the group consisting of ocular disease, cancer, chronic inflammatory or autoimmune disease, vascular anomaly, cardiovascular disease, fibrotic or connective tissue related condition, comprising administering a pharmaceutically effective amount of the pharmaceutical composition according to claim 5, to a subject in need thereof, wherein said pharmaceutical composition is administered alone or in combination with another therapeutic agent. 12. The method according to claim 8, wherein the another therapeutic agent is selected from the group consisting of antibodies, peptides, pepti-bodies, small molecules, chemotherapeutic agents such as cytotoxic and cytostatic agents, immunological modifiers such as interferons and interleukins, growth hormones or other cytokines, folic acid, vitamins, minerals, aromatase inhibitors, RNAi, Histone Deacetylase Inhibitors, and proteasome inhibitors. 13. The method according to claim 12, wherein the antibodies are selected from any one of bevacizumab and erbitux, and wherein the chemotherapeutic agent is at least one of cytotoxic and cytostatic agents, selected from any one of paclitaxel, cisplatin, vinorelbine, docetaxel, gemcitabine, temozolomide, irinotecan, 5FU, or carboplatin. 14. The method according to claim 8, wherein said peptide is administered by a means of administration selected from the group consisting of: intravascular, intravenous, injection, infusion, oral, enteral, rectal, pulmonary, inhalation, nasal, topical, transdermal, buccal, sublingual, intravesical, intravitreal, intraperitoneal, vaginal, brain, intra-cerebroventricular, intra-cerebral, convection enhanced diffusion, CNS, intrathecal, perispinal, intra-spinal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, transmucosal, or sublingual administration, or administration via an implant. 15. The method according to claim 14, wherein topical or transdermal administration of a said peptide includes ointments, pastes, creams, lotions, emulsions, gels, powders, solutions, sprays, inhalants, or patches. 16. The method according to claim 8 wherein the ocular disease is selected from the group consisting of retinal angiogenesis disorder, ocular neovascularisation, retinopathies, including diabetic retinopathy and retinopathy of prematurity, age-related macular degeneration, macular oedema, trachoma, glaucoma, dry eye syndrome, neuro-ophthalmic disease, oculosystemic disease, eye infections, eye inflammation and corneal neovascularization. 17. The method according to claim 8, wherein the cancer is selected from the group consisting of breast cancer, cervical cancer, ovary cancer, endometrial cancer, melanoma, bladder cancer, lung cancer, pancreatic cancer, colon cancer, prostate cancer, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma, multiple myeloma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, myeloid leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia, thyroid cancer, thyroid follicular cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcomas, melanoma, uveal melanoma, teratocarcinoma, neuroblastoma, glioma, glioblastoma, benign tumor of the skin, renal cancer, anaplastic large-cell lymphoma, esophageal squamous cells carcinoma, hepatocellular carcinoma, follicular dendritic cell carcinoma, intestinal cancer, muscle-invasive cancer, seminal vesicle tumor, epidermal carcinoma, spleen cancer, bladder cancer, head and neck cancer, stomach cancer, liver cancer, bone cancer, brain cancer, cancer of the retina, biliary cancer, small bowel cancer, salivary gland cancer, cancer of uterus, cancer of testicles, cancer of connective tissue, prostatic hypertrophy, myelodysplasia, Waldenstroms macroglobinaemia, nasopharyngeal, neuroendocrine cancer myelodysplastic syndrome, mesothelioma, angiosarcoma, Kaposis sarcoma, carcinoid, oesophagogastric, fallopian tube cancer, peritoneal cancer, papillary serous mullerian cancer, malignant ascites, gastrointestinal stromal tumor (GIST), and a hereditary cancer syndrome selected from Li-Fraumeni syndrome and Von Hippel-Lindau syndrome (VHL). 18. The method according to claim 8, wherein the cancer is invasive or metastatic. 19. The method according to claim 8, wherein the cancer is inflammation-induced cancer. 20. The method according to claim 8, wherein the vascular anomaly is selected from the group consisting of vascular permeability, plasma leakage, venous malformation (VM), hemangioblastoma, hemangiomas, intramuscular hemangiomas, brain arteriovenous malformations (BAVM), arteriosclerosis, thrombosis, leukomalacia (PLV), Hereditary Hemorrhagic telangiectasia (HHT), Ataxia telangiectasia and Osler-Weber syndrome. 21. The isolated peptide of claim 1, wherein said peptide inhibits binding of Tie2 to an angiogenic protein. 22. The isolated peptide of claim 21, wherein said angiopoietin is selected from the group consisting of angiopoietin 1, angiopoetin 2 and angiopoietin 4. 23. The isolated peptide of claim 1, wherein said peptide inhibits in-ovo angiogenesis in the chorio-allantoic membranes of a fertilized egg. 24. A method of treating an angiogenesis-related disease or condition selected from the group consisting of angiogenesis-related ocular disease and angiogenesis-related cancer, comprising administering a pharmaceutically effective amount of the peptide according to claim 1, to a subject in need thereof, wherein said peptide is administered alone or in combination with another therapeutic agent. 25. The isolated peptide of claim 1, consisting of an amino acid sequence as set forth in SEQ ID NO: 7 or a homolog or a derivative thereof, having at most 56 amino acids and wherein said peptide has antiangiogenic activity. 26. The isolated peptide of claim 1, consisting of an amino acid sequence as set forth in SEQ ID NO: 8 or a homolog or a derivative thereof, having at most 43 amino acids and wherein said peptide has antiangiogenic activity. 27. The isolated peptide of claim 1, consisting of an amino acid sequence as set forth in SEQ ID NO: 9 or a homolog or a derivative thereof, having at most 38 amino acids and wherein said peptide has antiangiogenic activity.

Details for Patent 9,255,132

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2028-07-21
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2028-07-21
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-07-21